C magnetic resonance spectroscopy (MRS)-detectable hyperpolarized pyruvate to lactate conversion was validated in cancer models as a noninvasive imaging method for the detection of tumors and treatment response, and is currently in phase I clinical trials. Importantly, responses to radiation, chemotherapy and targeted PI3K signaling inhibitors have all been associated with a drop in hyperpolarized lactate production, albeit via different mechanisms. The goal of this study was to assess the effect of treatment with another therapeutic approach entering the clinic, namely inhibition of the MAPK pathway. To this end we studied the effect of the MEK inhibitor U0126. Methods. Prostate (PC3) and breast (MCF-7) cancer cells were treated for 48 hours with the MEK inhibitor U0126 (50 and 25 μM, respectively). To monitor treatment-induced modulation of hyperpolarized pyruvate to lactate conversion, live cells grown on beads were investigated in a bioreactor system using 13 C MRS. Hyperpolarized pyruvate was delivered to the cells at 5 mM final concentration and single-transient 13 C MR spectra were immediately acquired every 3 s over a period of 300 s using 5° pulses. To determine treatment-induced changes in intracellular lactate levels, cells were extracted using the dual phase extraction and investigated by 1 H MRS at 600 MHz using a 90° pulse and 3 s relaxation delay with water suppression using presaturation or excitation sculpting. The effect of treatment on expression of lactate dehydrogenase A (LDHA) and monocarboxylate transporter-1 (MCT1) was probed using Western blotting. LDH activity and NAD(H) levels were determined using spectrophotometric assays based on detection of absorbance changes due to NADH consumption (340 nm) and reduction of thiazolyl blue (570 nm), respectively. Results. U0126 treatment lead to MAPK signal inhibition and inhibition in cell proliferation in both cell lines (data not shown). Figure 1A illustrates the temporal evolution of hyperpolarized lactate production in control and U0126-treated cells. The maximum hyperpolarized lactate levels in treated MCF-7 cells dropped to 62±26% (p=0.05) compared to control cells. In contrast, in PC3 cells treatment with U0126 induced an increase to 162±23% (p=0.02) of control. To mechanistically explain our findings, and in particular the unexpected increase in hyperpolarized lactate observed in PC3 cells in response to administration of U0126, we investigated treatmentinduced changes in the different factors known to affect pyruvate to lactate conversion, namely NADH concentration, total intracellular lactate levels, LDH expression and activity, and expression of MCT1. In both PC3 and MCF-7 cells NADH levels remained unchanged. Total intracellular lactate levels increased in both cell lines following treatment with U0126, to 134±16% (p=0.002) of control in PC3 and to 206±42% (p=0.001) in MCF-7 cells (Fig. 1B) . We also observed an increase in LDH expression (Fig. 1C) and activity to 136±18% (p=0.037), and to 245±38% (p=0.02) of control in PC3 and MCF-7 cells, respectively (Fig. 1D) . Finally, we assessed the expression of MCT1, which mediates pyruvate transport into the cell. While the above factors were all similarly modulated by drug treatment in both cell lines, when we probed for expression of MCT1 we observed a clear depletion of MCT1 in treated MCF-7 cells but unchanged levels in treated PC3 cells compared to controls (Fig. 1C) . Discussion and Conclusions. The elevation of LDH expression and activity as well as the elevation of total intracellular lactate could all contribute to the formation of higher levels of hyperpolarized lactate. Indeed, in PC3 cells we observed a treatment-induced increase in the hyperpolarized pyruvate to lactate conversion. In contrast and in spite of an even greater elevation of LDH expression and activity as well as total intracellular lactate levels in MCF-7 cells, we observed a drop in the pyruvate to lactate conversion in these cells. This was associated with a clear drop in cellular MCT1 levels. Thus, the reduction in hyperpolarized pyruvate delivery into the cytosol is likely the explanation for the drop in hyperpolarized lactate production observed following U0126 treatment in MCF-7, but not in PC3 cells. Our results highlight the complexity of the interactions between signaling pathways and metabolic pathways, and illustrate the need for a good mechanistic understanding of links between cell signaling and metabolism. Moreover, our findings demonstrate the value of the hyperpolarized
